Thyroid function monitoring during pregnancy in euthyroid women with thyroid autoimmunity.


Journal

Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413

Informations de publication

Date de publication:
01 Jul 2024
Historique:
received: 05 04 2024
accepted: 05 07 2024
medline: 5 7 2024
pubmed: 5 7 2024
entrez: 5 7 2024
Statut: aheadofprint

Résumé

Thyroid autoimmunity (TAI) may be present in 1-17% of pregnant women. Monitoring of thyroid function in euthyroid pregnant women positive for anti thyroperoxidase antibodies (TPOAb +) is recommended. To determine the prevalence and possible clinical and biological risk factors of biochemical progression (rise in serum TSH> 2.5 mU/L) at second blood sampling during pregnancy, in euthyroid women (TSH ≤ 2.5 mU/L) according to their TPOAb status. This study included demographic and biological data from two previously published cohorts (n=274 women from August 1996 to May 1997 Copenhagen cohort, and n=66 women from January 2013 to December 2014 Brussels cohort) having at least two measurements of TSH and free thyroxine (FT4) and at least one of TPOAb during spontaneously achieved singleton pregnancies. The majority of women studied did not show biochemical progression. Only 4.2% progressed, significantly more frequently among TPOAb + women, as compared to TPOAb - group (9.4% vs 2.7%, p=0.015). No rise in serum TSH > 4 mU/L at 2nd sampling was observed. Higher baseline TSH levels were associated with biochemical progression in both TPOAb+ (p=0.05) and TPOAb - women (p<0.001), whereas maternal age, BMI, multiparity, smoking, FT4 and TPOAb concentrations were not significantly different between women with and without progression. Only a minority of euthyroid women with thyroid autoimmunity presented biochemical progression and none with a TSH > 4mU/L. Larger studies are needed to better target the subset of women that would benefit most from repeated thyroid function monitoring during pregnancy.

Sections du résumé

BACKGROUND BACKGROUND
Thyroid autoimmunity (TAI) may be present in 1-17% of pregnant women. Monitoring of thyroid function in euthyroid pregnant women positive for anti thyroperoxidase antibodies (TPOAb +) is recommended.
OBJECTIVE OBJECTIVE
To determine the prevalence and possible clinical and biological risk factors of biochemical progression (rise in serum TSH> 2.5 mU/L) at second blood sampling during pregnancy, in euthyroid women (TSH ≤ 2.5 mU/L) according to their TPOAb status.
METHODS METHODS
This study included demographic and biological data from two previously published cohorts (n=274 women from August 1996 to May 1997 Copenhagen cohort, and n=66 women from January 2013 to December 2014 Brussels cohort) having at least two measurements of TSH and free thyroxine (FT4) and at least one of TPOAb during spontaneously achieved singleton pregnancies.
RESULTS RESULTS
The majority of women studied did not show biochemical progression. Only 4.2% progressed, significantly more frequently among TPOAb + women, as compared to TPOAb - group (9.4% vs 2.7%, p=0.015). No rise in serum TSH > 4 mU/L at 2nd sampling was observed. Higher baseline TSH levels were associated with biochemical progression in both TPOAb+ (p=0.05) and TPOAb - women (p<0.001), whereas maternal age, BMI, multiparity, smoking, FT4 and TPOAb concentrations were not significantly different between women with and without progression.
CONCLUSIONS CONCLUSIONS
Only a minority of euthyroid women with thyroid autoimmunity presented biochemical progression and none with a TSH > 4mU/L. Larger studies are needed to better target the subset of women that would benefit most from repeated thyroid function monitoring during pregnancy.

Identifiants

pubmed: 38967388
doi: 10.1530/EC-24-0151
pii: EC-24-0151
doi:
pii:

Types de publication

Journal Article

Langues

eng

Auteurs

Aglaia Kyrilli (A)

A Kyrilli, Department of Endocrinology, Hôpital Universitaire de Bruxelles- Hôpital Erasme, Brussels, Belgium.

Bernard Corvilain (B)

B Corvilain, Department of Endocrinology, Hôpital Universitaire de Bruxelles- Hôpital Erasme, Brussels, Belgium.

Sofie Bliddal (S)

S Bliddal, Department of Medical Endocrinology and Metabolism, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark.

Dorthe Hansen Precht (DH)

D Precht, Department of Medical Endocrinology and Metabolism, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark.

Ulla Feldt-Rasmussen (U)

U Feldt-Rasmussen, Department of Endocrinology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Kris G Poppe (KG)

K Poppe, Endocrinology, Centre Hospitalier Universitaire Saint-Pierre, Bruxelles, Belgium.

Classifications MeSH